The prognosis of patients with gastric carcinomas at an advanced stage still remains dismal, and therefore novel therapeutic modalities are urgently needed. Since the successful targeting of amplified ERBB2 with a humanized monoclonal antibody, the amplified genes of other receptor tyrosine kinases such as EGFR, FGFR2, and MET, as well as those of other cell regulator genes, are being considered as candidate targets of molecular therapy. The aim of the present study was to determine the amplification status of 26 genes, which are frequently amplified in solid cancers, in advanced gastric cancers. A total of 93 formalin-fixed and paraffin-embedded advanced gastric cancer tissues were examined by multiple ligation-dependent probe amplification, and 32 cases with 'gain' or 'amplified' status of 16 genes were further examined for the respective gene amplification by fluorescence in situ hybridization (FISH) and for the respective protein overexpression by immunohistochemistry. The frequencies of gene amplifications in advanced gastric cancers were as follows: ERBB2 (13 cases, 14%), FGFR2 (7 cases, 8%), MYC (7 cases, 8%), TOP2A (7 cases, 8%), MET (4 cases, 4%), MDM2 (4 cases, 4%), CCND1 (3 cases, 3%), FGF10 (2 cases, 3%), and EGFR (1 case, 1%). Amplification of the receptor tyrosine kinases genes occurred in a mutually exclusive manner except for one tumor in which ERBB2 and FGFR2 were both amplified but in different cancer cells. Co-amplification of ERBB2 and MYC, and EGFR and CCND1, in single nuclei but on different amplicons, was confirmed in one case each. Attempts at correlating the FISH status with the immunohistochemical staining pattern showed variable results from complete concordance to no correlation. In conclusion, combination of multiple ligation-dependent probe amplification and FISH analysis is a feasible approach for obtaining the semi-comprehensive genetic information that is necessary for personalized molecular targeted therapy.
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In 2009 , an open-label, international phase 3, randomized controlled trial (ToGA, Trastuzumab for gastric cancer) found that the addition of trastuzumab, a humanized monoclonal antibody that binds to the extracellular juxtamembrane domain of a receptor tyrosine kinase, ERBB2, (otherwise known as the human epidermal growth factor receptor 2), to cisplatin-based chemotherapy significantly improved the overall survival of advanced gastric cancer patients with overexpressed and/or amplified ERBB2 as compared with chemotherapy alone. 4 To date, targeting ERBB2-overexpression/amplification remains the only successful and approved targeted therapy for gastric cancer. However, there is an urgent need for other inhibitors to be investigated for the therapy of many of the unique molecular subtypes of gastric cancer. 5 In particular, FGFR2 and MET, which encode RTKs similar to ERBB2, are considered as strong candidate targets because their amplification is associated with advanced stages, 6, 7 and furthermore, the amplification of FGFR2 was preferentially found in a poorly differentiated subtype. 8, 9 In preclinical studies, cells with amplified FGFR2 or MET showed overexpression of their respective proteins, and inhibitors to these receptors were shown to effectively block their downstream signal transduction and induce apoptosis. [10] [11] [12] [13] [14] At present, apart from ERBB2 targeting, approaches for targeting MET and FGFR2 are the most clinically advanced of prospective targeted therapy. However, the prevalence of amplification of each of these genes, as assessed by oligonucleotide array comparative genetic hybridization, real-time PCR, fluorescence in situ hybridization (FISH), or silver in situ hybridization is low, ie, from 2 to 5% for FGFR2, 9, 10, 12, 14 and from 2 to 8% for MET, respectively. 6, 7, 14, 15 Intriguingly, a recent comprehensive genome-wide analysis of copy number alterations using an single nucleotide polymorphism array 13 showed that amplification of FGFR2, EGFR, ERBB2, and MET occurred mutually exclusively and that other genes such as MYC and CCND1 were also amplified in gastric cancer. When considering promising targets of molecular therapy, the apparently low prevalence of these gene amplifications in gastric cancer makes selection of the right set of patients that can benefit from targeted therapy a difficult challenge.
Multiplex ligation-dependent probe amplification is a new, high-resolution method for detecting numerous copy number variations in genomic sequences in a single reaction and requires only small amounts of DNA extracted from formalin-fixed paraffin-embedded tissues. 16, 17 This technique makes possible the simultaneous detection of the amplification status of ERBB2, EGFR, MET, MYC, CCD1, and MDM2. 16 The aims of the present study were to determine the gene amplification status of RTKs and other cell regulator genes including ERBB2, EGFR, FGFR2, MET, MYC, CCND1, and MDM2 in advanced gastric cancers with a view toward future introduction of molecular targeted therapy, and to examine the usefulness of multiplex ligation-dependent probe amplification in the semi-comprehensive detection of these gene amplifications.
Materials and methods

Patients
A total of 93 advanced gastric adenocarcinoma patients out of 262 gastric cancer patients who underwent surgery at the Department of Surgery in Kanazawa University Hospital between 2011 and 2013 were examined. Cancer staging was performed according to the TNM cancer staging system of the American Joint Committee of Cancer. 18 The World Health Organization Classification of Tumors 19 was used to determine histological classification as differentiated (tubular adenocarcinoma, papillary adenocarcinoma) or undifferentiated adenocarcinoma (mucinous adenocarcinoma, poorly cohesive carcinomas, mixed carcinoma, carcinoma with lymphoid stroma and unclassified carcinoma). This laboratory study was approved by the Medical Ethics Committee of Kanazawa University (Approval No 181), and written informed consent was obtained from all patients. Serial sections cut from representative formalin-fixed and paraffin-embedded cancer tissues were used for hematoxylin-eosin staining, multiplex ligation-dependent probe amplification, FISH, and immunohistochemistry.
Multiplex Ligation-Dependent Probe Amplification
A cancer area was selected on a 6 μm-thick representative tumor section, with reference to the adjacent hematoxylin-eosin staining section, taking care that non-neoplastic cells were excluded as much as possible. DNA was extracted manually from each section using proteinase K (Rosch Diagnostics, Manheim, Germany) according to the manufacturer's (MRC-Holland, Amsterdam, The Netherlands) protocol. By using this protocol, 41 μg of sample DNA with an OD 260 :OD 280 ratio within 1.1-1.7 was obtained from each tumor. DNA from the cell lines MKN7, A431, KATOIII, HSC39, and MKN45, which were previously shown to display amplified ERBB2, EGFR, FGFR2, FGFR2 and MYC, and MET, respectively, were used as positive controls. 8, 20 Multiplex ligation-dependent probe amplification analysis was performed by using two kits from MRCHolland. The SALSA MLPA KIT P175-A2 TumorGain kit contains two or three probes for each of 24 genes including ERBB2, EGFR, MET, MYC, CCND1, MDM2, and TOP2A. The SALSA MLPA probemix P231-A2 FGF10-FGFR2, which was originally used for the diagnosis of autosomal dominant lacrimoauriculodentodigital syndrome, 21 contains five probes each for FGFR2 and FGF10. The PCR products were separated on an ABI-310 capillary sequencer (Applied Biosystems, Foster City, CA, USA) and interpreted with Genemapper software (Applied Biosystems). Data analysis was performed with Coffalyser MLPA-DAT software (version 9.4, MRCHolland) to generate normalized peak values.
Average peak values below 0.7 were defined as 'lost', between 0.7 and 1.3 as 'normal', between 1.3 and 2.0 as 'gain', and 42.0 as 'amplified', as previously established. 16, 17 
FISH
Tumors with 'amplified' or 'gain' of genes as determined by multiplex ligation-dependent probe amplification were further examined using FISH to validate the accuracy of the multiplex ligationdependent probe amplification results for the respective gene amplification. FISH probes acquired from BACPAC Resources (Oakland, CA, USA) are summarized in Table 1 . The probes were labeled with SpectrumOrange or SpectrumGeen using a nick translation kit (Abbott Laboratories, Abbott Park, IL, USA). For the detection of gene amplification, a SpectrumGreen-labeled pericentromeric probe (Abbott), specific to each chromosome on which the particular gene was located, was co-hybridized to standardize the chromosome number. Tumors exhibiting co-amplification of different genes were further examined by simultaneous hybridization with two probes specific to the genes that were labeled with different fluorescent markers to determine the coexistence of the amplified genes in single cells and single amplicons.
Removal of protein from the tissue sections, denaturation, hybridization, and post-hybridization washing were performed as described previously. 17 The tissue sections were counterstained with DAPI II (Abbott) and examined using a fluorescence microscope (Olympus, Tokyo, Japan) equipped with a Triple Bandpass Filter set (Abbott) for DAPI II, SpectrumOrange and SpectrumGreen, and a filter set specific for SpectrumOrange or SpectrumGreen. FISH images were recorded through a cooled chargecoupled device camera (DP-70, Olympus) linked to a computer software program (DP Manager, Olympus).
Scoring and evaluation of FISH slide were performed manually by counting gene signals and the centromere signals, on which the gene was located, of 20 tumor nuclei per case. The average copy number of the gene and the centromere, and their ratio, were determined for each case. Gene amplification was determined according to the American Society of Clinical Oncology/College of American Pathologists-approved criteria of ERBB2 amplification, except that the quantity of positive cells was defined as more than six gene copies per nucleus or gene signals/centromere signals 42.2. 22 In addition, low-level amplification was arbitrarily defined as gene signals/centromere signals 42.2 and gene copy number of o 6, and high polysomy was arbitrarily defined as gene signals/centromere signals o 1.8 and gene copy number 46. In cases of apparent intratumoral heterogeneity in gene amplification, the fractions (%) of the tumor cells containing gene Table 1 Genes with increased copy number ('amplified' or 'gain') detected by multiplex ligation-dependent probe amplification in advanced gastric cancer Name of gene 5 (1) 5 (0) 4 (3) 2 (0) 16 (0) 2 (0) 10 (6) 10 (5) 0 (0) 2 (0) 19 (3) 5 (3) 13 (4) 15 (0) 21 (0) Values in parentheses are the numbers of tumors with gene amplification detected by FISH.
amplification were scored using broad tiers of o 30, 30-70, and 470%.
Immunohistochemistry
Immunohistochemistry for ERBB2, EGFR, FGFR2, MET, MYC, CCND1, and MDM2 was performed on tumors with FISH-proved amplification. The antibody clones, manufacturers and dilutions, and the antigen retrieval methods are summarized in Table 2 . Antibody binding was visualized using the LSAB system (Dako, Glostrup, Denmark). For evaluation of positive staining of ERBB2, EGFR, FGFR2, and MET, each tumor, or portion of tumor, was scored using a four-tier system (0, 1+, 2+, 3+) according to the criteria recommended by Dako for the HercepTest, except that the quantity of positive cells was not considered. For evaluation of MYC, CCND1, and MDM staining, only nuclear immunostaining, which was significantly higher than that of control cells of normal gastric mucosa, was considered as positive.
Statistical Analyses
The association of gene amplification and histology of the tumor, and association between amplifications of different genes were analyzed for significance using either Fischer's exact probability test or the χ 2 -test.
Results
Multiplex Ligation-Dependent Probe Amplification
Multiplex ligation-dependent probe amplification analyses were successfully performed on all 93 of the formalin-fixed and paraffin-embedded advanced gastric adenocarcinoma tissue samples. The gene status of the 26 genes analyzed in the 93 tumors were categorized as 'amplified', 'gain', or 'normal' based on the mean multiplex ligation-dependent probe amplification peak values. There were no cases with 'lost' genes. The number of tumors with 'amplified' or 'gain' of specific genes by multiplex ligation-dependent probe amplification analysis is summarized in 23 Cancer nuclei with colocalization of an amplified gene and the amplified centromeric lesion on which the gene is located, which results in a yellow fusion signal 24 as shown in Supplementary  Figure 1 , was rarely observed. Approximately half of the gene amplifications occurred in an intratumoral heterogeneous fashion.
All tumors with genes that were categorized as 'amplified' by multiplex ligation-dependent probe amplification had cancer cells with gene amplification that could be detected by FISH as shown in Table 1 . The tumors with 'gain' of MDM2, SMO, BRAF, FGFR1, CDK4, AURKA, and AR by multiplex ligation-dependent probe amplification showed polysomy of the chromosome on which the target gene is located; however, amplification of these genes was not found. Table 3 describes the clinicopathological characteristics of the 32 tumors with gene amplification and indicates the fraction (%) of the amplified cells and the type of amplification in each case. Three quarters (24 of 32) of the amplifications were of genes encoding RTKs: representative FISH images of amplified ERBB2, FGFR2, MET, and EGFR were shown in Figure 1a and b, Figures 1a and 2a, Figure 3a and c, and Figure 4a , respectively. Except for Case 7, amplification of these RTK genes occurred in a mutually exclusively manner, ie, each tumor had a single RTK gene mutation. In Case 7, dual-color FISH analysis demonstrated 'homogeneously staining region'-type ERBB2 amplification and 'double minute chromosome'-type FGFR2 amplification intermingled in a mosaic pattern. However, no single cell Figure 1a . MYC was amplified in seven tumors, and was co-amplified with ERBB2 in three tumors. On the basis of dual-color FISH analysis, coamplification of ERBB2 and MYC in single nuclei but on different amplicons was confirmed in case 9 (Figure 1b) . MDM2 amplification was found in four tumors; one showed co-amplification with ERBB2 and the other showed co-amplification with the FGFR2; however, cancer cells with different gene amplification occupied different tumor areas as shown in Figure 2 . CCND1 was amplified in three tumors; one showed co-amplification with EGFR and the other with FGFR2. Dual-color FISH analysis could confirm co-amplification of EGFR and CCND1 in single nuclei but on different amplicons in case 24 ( Figure 4a) . All of the tumors with TOP2A amplification were also positive for ERBB2 amplification. Furthermore, dual-color FISH showed that TOP2A signals and ERBB2 signals were closely associated (Supplementary Figure 2) .
Immunohistochemistry. Immunohistochemistry for ERBB2 indicated 11 tumors with 3+ or 2+ staining (Figure 1e ), one tumor with 1+ staining (Case 7) (Figure 1c ) and one tumor (case 10) was negative. Immunohistochemistry for FGFR2 displayed a variety of cytoplasmic staining from weak to strong, which was found to correspond to FGFR2-amplified tumor cells (Figures 1d and 2d) . However, similar cytoplasmic staining was also commonly found in non-FGFR2-amplified cancer cells (Figure 2a Figure 3a and b. In Case 22, MET-amplified and non-amplified cells were in different areas and both showed 2+ MET immunostaining. Thus these cells were not differentiated by immunohistochemistry as shown in Figure 3e and f. Case 24 that showed homogeneous EGFR amplification showed 3+ immunostaining of the EGFR (Figure 4b) .
Most immunohistochemical results of MYC were equivocal (Figure 1f) . In the immunohistochemistry analysis of MDM2 and CCND1, scattered positive nuclear staining was found and clear coincidence of this staining with the respective amplificationpositive nuclei was not confirmed (Figure 2c and e, Figure 4a and c, respectively) .
Clinicopathological Findings. Amplification of ERBB2 was significantly more frequent in differentiated carcinomas than in undifferentiated carcinomas (P = 0.04); however, the amplification of other genes showed no correlation with histological differentiation.
Discussion
In the present study, 32 of a total of 93 advanced gastric cancers (34%) displayed definite gene amplification and most of this amplification occurred in a FISH pattern that was reminiscent of cytogenetic homogeneously staining region or double minute chromosomes. Furthermore, 26% (24 of 93) of the amplifications were amplification of one of four genes (ERBB2, FGFR2, MET, and EGFR) that encode a RTK. The frequencies of these gene amplifications were not significantly different from those previously reported for ERBB2, FGFR2, 9,10,12,14 MET, 6, 7, 14, 15 and EGFR. 6, 20 It is intriguing that, except for case 7, RTK gene amplification occurred in a mutually exclusive manner. Even in Case 7, RTK gene co-amplification did not occur in the same cells. Thus, if a common tyrosine kinase inhibitor to the four RTKs were available, 24 of 93 (26%) cases of advanced gastric cancer would potentially be susceptible to that agent. This characteristic of RTKs is one of the reasons why RTK gene amplifications have attracted much attention as molecular targets even though the prevalence of individual RTK gene amplification is low. 6, 12, 13 However, if small fractions of amplified cells that cannot be detect by screening with multiplex ligation-dependent probe amplification and/or early gastric cancers are included, co-amplification of RTK genes is not exceptional in gastric cancers. On the contrary, our previous study showed a marginal trend for co-amplification of EGFR and ERBB2; however, this trend was not statistically significant. 25 In our more recent study in which we examined the co-amplification of ERBB2 and other RTK genes, we found that of 51 tumors with ERBB2 amplification, 14% (7/51) of the tumors displayed co-amplification with EGFR, one tumor showed coamplification with FGFR2, and one tumor showed co-amplification with MET and FGFR2. 16 It is probable that redundancy of RTKs, which are unnecessary for cancer cell growth, diminishes in the course of gastric cancer progression.
In contrast to the lack of co-amplification of RTK genes, MYC, and RTK genes are occasionally coamplified in single cancer cells. In the present study co-amplification of MYC and ERBB2 in the same cell was found in three tumors, and, in our previous study, co-amplification of MYC and ERBB2 or EGFR occurs in a non-incidental manner. 25 Thus, these coamplifications may be of some merit for survival of cancer cells. A similar selective co-amplification of ERBB2 and MYC was found in breast cancer cells and it has been speculated that this co-amplification might be a very favorable prognostic factor when combined with adjuvant therapy by trastuzumab. 26, 27 However, this hypothesis was recently refuted. Instead, new data have shown that this coamplification is associated with poor outcome and is associated with the sequence of acquisition of a malignant stem cell-like phenotype that maintains lower growth and therefore may be a key target of new therapy. 28 TOP2A resides very close to ERBB2 on the chromosome and its amplification was only observed with the concomitant amplification of ERBB2. However, TOP2A is not simply a 'passenger' gene because TOP2A encodes an enzyme, topoisomerase IIα, which is required for DNA replication. Moreover, clinical studies have confirmed that breast cancer patients with TOP2A gene amplification are more sensitive to topoisomerase IIα-based therapy. 29 Unfortunately this therapy is not commonly used for the treatment of gastric cancers in Japan.
Information regarding CCND1 amplification is useful because expression of CCND1 may cause resistance to cisplatin, 30 which was coadministered with trastuzumab in the ToGA clinical trial. To the best of my knowledge, this is the first report of amplification of FGF10 in gastric cancer. Although stomach development is dependent on FGF10-and FGFR2-mediated signaling, 31 it remains to be clarified whether FGF10 amplification is relevant to carcinogenesis of gastric cancer through enhanced signaling. In this study an additional candidate for molecular targeting, amplified MDM2, was found in ERBB2-non-amplified gastric cancers. MDM2 is an oncogene whose expression controls tumorigenesis by promoting degradation of the tumor suppressor protein p53. Amplification of MDM2 impacts cancer treatments that use selective inhibitors of MDM2 proteins. 32, 33 Indeed, in an in vivo study, treatment with nutlin, an MDM2 antagonist, induced p53-dependent transcription and apoptosis in liposarcoma cells that were positive for MDM2 amplification. 34 In this study we screened advanced gastric carcinomas for possible gene amplification by multiplex ligation-dependent probe amplification and confirmed the results obtained using FISH analysis, which has been considered as the gold standard method for analysis of gene amplification. FISH probes span~200 kb of DNA sequence, which is similar to or several-fold larger than the target gene size. In contrast, multiplex ligation-dependent probe amplification targets intragenic portions of DNA sequence with sequence sizes of 50-100 bases. Although for a typical gene amplification the result of multiplex ligation-dependent probe amplification should theoretically coincide with that of FISH, the copy number detected by multiplex ligationdependent probe amplification was often lower than that detected by FISH owing to intratumoral heterogeneity and/or contamination of non-neoplastic DNA. In the present study, the cutoff value of 1.3 that was recommended by the multiplex ligationdependent probe amplification kit manufacturer was used for all of the genes. Although all of the cases defined as 'amplified' by multiplex ligationdependent probe amplification were also amplified by FISH analysis, seven genes that were defined as 'gain' by multiplex ligation-dependent probe amplification showed no real amplification by FISH analysis (Table 1 ). It may therefore be possible to increase the specificity of the test by resetting the cutoff values for these genes. 35 However, for the purpose of screening of gene amplification, high sensitivity precedes specificity and the cutoff value of 1.3 was very acceptable for such screening.
MYC, CCND1, MDM2, ERBB2, EGFR, FGFR2, and MET are considered to be involved in carcinogenesis through protein overexpression of amplified genes. Thus, immunohistochemistry that is familiar to most diagnostic pathologists might be the first choice for examination of these aberrations. However, our attempts to correlate FISH status with immunohistochemical staining resulted in variable correlations between the two types of measurement ranging from complete correspondence to dissociation. The protein overexpression of MYC, CCND1, and MDM2 is regulated by several pathways and thus gene amplification may not necessarily provide a straightforward correlation with protein overexpression. As for RTK genes, the hypothesis that 'amplification causes overexpression' is fundamentally established for ERBB2, and is highly supported for EGFR, FGFR2, and MET. [10] [11] [12] [13] [14] However, even for RTKs, inconsistent results between FISH and immunohistochemical analyses were often obtained, mostly because of inherent technical reasons of immunohistochemistry such as specificity of antibodies, fixative used, duration of fixation, staining procedures, and/or scoring system. Therefore, at the present time gene amplification provides the best biomarkers for helping to select the right patient candidate for molecular therapy targeted toward these genes, and multiplex ligation-dependent probe amplification is the most feasible method for screening these gene amplifications.
In conclusion, given the apparent low prevalence of amplification of candidate target oncogenes for therapy of gastric cancer, implementation of semi-comprehensive screening by multiplex ligation-dependent probe amplification followed by confirmatory FISH analysis should facilitate the identification of patients who may benefit from such tailored therapy. 
